Navigation Links
Studies advance knowledge of HIV impact on hepatitis C infection and genes that may thwart HCV
Date:3/4/2013

Infectious disease experts at Johns Hopkins have found that among people infected with the hepatitis C virus (HCV), co-infection with HIV, speeds damage and scarring of liver tissue by almost a decade.

In a second study of HCV infection, the Johns Hopkins research team participated in the discovery of two genetic mutations that make it more likely that patients' immune systems can rid the body of HCV. Both studies are described in articles published online in February ahead of print in the journal Annals of Internal Medicine.

"Our latest study results suggest that HIV might promote aging and disease progression in people with HCV," says infectious disease specialist and senior investigator, David L. Thomas, M.D., M.P.H. Thomas, who is the Stanhope Bayne-Jones Professor and director of infectious diseases at the Johns Hopkins University School of Medicine and a professor at the university's Bloomberg School of Public Health, says that among 1,176 study participants, those co-infected with HCV and HIV showed the same severity of liver fibrosis and cirrhosis as those who were infected only with HCV but were 9.2 years older. All study participants were current and former intravenous drug users from Baltimore whose health and disease progression were being monitored with bi-monthly check-ups and liver tissue samples taken from 2006 to 2011.

The United States Centers for Disease Control and Prevention estimates that a quarter of the 3.2 million Americans chronically infected with HCV are also infected with HIV.

"There has been a growing hypothesis that HIV may accelerate the aging process, resulting in an earlier onset of chronic disease, including cancer, cardiovascular and liver disease. Until now, there have not been strong data to support this theory," says study lead investigator and infectious disease epidemiologist Gregory Kirk, M.D., Ph.D., M.P.H.

"There has been concern that increased chronic diseases in people aging with HIV may simply reflect their greater exposure to alcohol, tobacco or illicit drugs," adds Kirk, an associate professor at the Johns Hopkins Bloomberg School of Public Health. "Importantly, this investigation showed an increased severity of liver disease among people with HIV compared to people without HIV but whose pattern of smoking, alcohol drinking and illicit drug use was very similar."

"Co-infected patients may have to be monitored more closely for worsening liver disease, and may require earlier and more aggressive treatment than people without HIV infection," adds study co-investigator and epidemiologist Shruti Mehta, Ph.D., M.P.H. Although the reason for the accelerated rate of liver disease with HIV is unclear, the study results suggest that HIV and aging may share common mechanisms of immune activation that speed up HCV disease progression, says Mehta, an associate professor at the Bloomberg School of Public Health. Mehta and Kirk are both co-principal investigators of the long-term monitoring of the Baltimore group, known as the ALIVE cohort, which is short for the AIDS Linked to the IntraVenous Experience study.

The second study is believed to be the largest genetic investigation ever conducted of people infected with HCV. In it, researchers at 13 medical centers in five countries, including Thomas' Johns Hopkins team, analyzed nearly 800,000 differences in the genetic code among 919 people whose immune systems showed antibody evidence of having successfully fought off HCV infection, and another 1,482 people who became infected with the disease.

Lead study investigator and genetic epidemiologist Priya Duggal, Ph.D., M.P.H., says 40 percent of people exposed to HCV, predominantly of white and Asian ancestry, "spontaneously fight off infection" without any need for drug therapy, suggesting a genetic basis to risk of infection.

The international team's analysis showed that 15 percent of study participants who failed to become infected with HCV had either or both of two genetic variants, one near the gene for interleukin-28B and the other near the genes for HLA class II. Duggal, an assistant professor at the Bloomberg School of Public Health, says this information may help explain "with a relatively high degree of genetic certainty" why racial differences exist among those who do become infected. However, she cautions that further research is needed to determine the full impact of these genetic variants on preventing and treating HCV in people of different ethnicities.

Thomas says the findings may help physicians predict the people who are most likely to self-recover from exposure to HCV, and those who will most likely require aggressive treatment right away.

HCV infection is the nation's leading cause of liver failure, liver cancer and liver transplantation. The disease, transmitted by contact with blood and other bodily fluids of an infected person, and through sexual activity, injection drug use or sharing of personal care items, kills more than 10,000 Americans annually. An estimated 185 million people worldwide are infected with HCV.


'/>"/>

Contact: David March
dmarch1@jhmi.edu
410-955-1534
Johns Hopkins Medicine
Source:Eurekalert

Related medicine news :

1. AIDS journal publishes findings of 2 important studies in Mar. 2013 issue
2. Research Foundation for Tick-Borne Infections Fights Lyme Disease, Babesiosis and Encephalitis with Pilot Studies
3. Hospital Readmissions All Too Common, U.S. Studies Find
4. Novel gene-searching software improves accuracy in disease studies
5. PLEXERA® LLC Launches Contract Research Services Business for Biomolecular Interaction Studies
6. Studies provide new insights into brain-behavior relationships
7. U.S. Launches Extensive Alzheimers Studies
8. FDA Urges Studies on Safer Formulations of Narcotic Painkillers
9. Boredom at Work Can Spur Creativity, Studies Find
10. Implant Overdentures - Dr. Jonathan Penchas Has Examined Studies That Show a High Success Rate and Advantages over Long Period
11. Previous studies on toxic effects of BPA couldnt be reproduced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... ... Delaware farmer Rick Dickerson attended the 2017 Soybean Leadership College ... a thousand acres of soybeans, corn and wheat, and raises peas, sweet corn, baby ... for the fresh market. He also operates a roadside stand and raises broilers for ...
(Date:1/18/2017)... FORT LAUDERDALE, FL (PRWEB) , ... January 18, ... ... and how to manage it from the number one doctor-recommended OTC antiperspirant, Certain ... population and often go untreated. , Certain Dri created this infographic to explain ...
(Date:1/18/2017)... ARBOR, Mich. USA; SAN JOSE, Calif, USA; and SHANGHAI, China ... ... (PRWEB) January 18, 2017 -- Global public health ... to reduce arsenic V (pentavalent arsenic) to NSF/ANSI 53: Drinking ... for drinking water treatment units. This certification verifies that MicroCeramics’ ...
(Date:1/18/2017)... ... January 18, 2017 , ... The V Foundation for Cancer Research, ... official endurance training and fundraising team, to compete in the Boston Marathon on April ... to finish the world’s oldest annual marathon to join Team V and support the ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... announce that their Vice President of Franchise Development, Paula Turner Pizarro, was recently ... business program, which features the insights of top business leaders from across the ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 2017  EnteroMedics Inc. (NASDAQ: ETRM ... technology to treat obesity, metabolic diseases and other ... underwritten public offering of units for gross proceeds ... and commissions and offering expenses payable by EnteroMedics. ... A Units, priced at a public offering price ...
(Date:1/18/2017)...  Adaptive Sound Technologies, Inc. (ASTI), the leading supplier ... Hyatt Place Nashville/Downtown to deliver the best sleep experience ... machines in over two hundred of its guest rooms. ... of having a great stay is sleeping well," said ... Nashville/Downtown. "We,re pleased to be able to offer our ...
(Date:1/18/2017)... 18, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, announces dosing the ... a Phase 2 acne rosacea study. DMT210 is ... proinflammatory cytokines in the skin responsible for the ... This clinical trial, DMT210-003, is a ...
Breaking Medicine Technology: